15-05-2012

Drugs giant GlaxoSmithKline is to take full control of Cellzome, a company specialising in the study of protein structures and functions.

09-05-2012

- Weir and Sage fall heavily - ITV, Sainsbury, Glencore higher after updates - Footsie hits new YTD lows on euro concerns

09-05-2012

- Eurozone political uncertainty still ongoing - ITV, Sainsbury, Glencore wanted after updates - Weir and Sage fall sharply

09-05-2012

GlaxoSmithKline has taken an offer of 13 dollars a share directly to the shareholders of Human Genome Sciences (HGS).

09-05-2012

City sources predict the FTSE 100 will open up 12 points from yesterday's close of 5,555, somewhat paring loses of 101 points in the previous session as political uncertainty in Greece continues to demoralise investors across Europe.

03-05-2012

Afren, Carnival, CSR, Fenner, Ferrexpo, GlaxoSmithKline, HSBC, Kesa, Legal & General, Mondi, Morrisons, Premier Farnell, Randgold, Regus, Rexam, S&N, Schroders, St James's Place, TUI

02-05-2012

The cupboard was very bare this morning for share tips, only the Telegraph had a stock tip:

01-05-2012

Tempus in the Times likes Aberdeen Asset Management. It's grown its AUM (assets under management) figure both through deals, and latterly through organic growth and has now made it into the FTSE 100.

26-04-2012

Admiral, Astra, Barclays, Berendsen, Capita, Dixons, Howden, HSBC, Glaxo, Go-Ahead, Ladbrokes, Lloyds, UBM, Unilever, Whitbread, William Hill

25-04-2012

- UK back in recession, GDP figures show - Markets await FOMC statement - Miners gain after China says growth will be 'robust'

25-04-2012

Miners were in demand following comments from Chinese Prime Minister Wen Jiabao that the government is committed to reforms in the country that are expected to ensure growth in the second-largest economy in the world remains robust.

25-04-2012

Drugs giant GlaxoSmithKline saw a modest increase in group revenue in the first quarter of 2012 as growth in the US, Emerging Markets/Asia Pacific (EMAP) and Japan offset declines in Europe.

24-04-2012

First quarter results from drugs giant GlaxoSmithKline are due out at noon on Wednesday, with both sales and profits expected to be higher than a year ago.

24-04-2012

ARM, Associated British Foods, Barclays, BBA, Carpetright, FirstGroup, Glaxo, Man, Microgen, Reed Elsevier, Stagecoach, Vectura

20-04-2012

Barclays kicks off the banking results season on Thursday, while the pharmaceuticals giants are also putting the finishing touches to their trading statements, with Glaxo, Astra and Shire all set to give first quarter updates.

20-04-2012

GlaxoSmithKline's shareholders are set for another return of capital this year following the divestment of more non-core over-the-counter (OTC) brands in its international markets to Aspen Pharmacare Holdings.

20-04-2012

The determination to find new blockbuster drugs has encouraged GlaxoSmithKline to bid $2.6 billion for a company that it admits has uncertain prospects. GSK has offered to buy its long-term partner Human Genome Sciences for $13 a share, an 81 per cent premium to the previous day's price. The companies have created drugs together since Human Genome was founded 20 years ago. GSK wants to reduce costs and squeeze the full benefit from their products. Human Genome, based in Maryland, said that it had rejected the approach but had initiated a strategic review. GSK has been invited to take part in that process — a move that puzzled Wall Street yesterday. The assumption was that GSK would get its way at a higher price. Human Genome's share price doubled to $14.44 in morning trading in New York. "We believe that a takeout from GSK makes strategic sense," analysts at Barclays Capital said, The Times says.

19-04-2012

- Stocks close down for a second day - Jobless data disappoints - Europe woes persist

19-04-2012

- Stocks wobble after US data, French rumours - Spanish auction strong - Cable and Wireless Worldwide extends offer deadline

19-04-2012

GlaxoSmithKline has confirmed it made an offer on April 11th to purchase US biopharmaceutical firm Human Genome Sciences, but has seen its bid 'rejected without discussion'.